Australia Suspends Breast Implants Over Cancer Risk Fears
Conditions have also been imposed on sponsors of products on the market
Executive Summary
The Therapeutic Goods Administration has now decided to take regulatory action on breast implants and tissue expanders following its review into the link between these products and a rare type of cancer.
You may also be interested in...
Worldwide Recall On Allergan Textured Breast Implants
Allergan PLC announced that it would take its Biocell textured breast implants and tissue expanders off the market worldwide shortly after the US FDA released additional information linking the use of the implants to a rare cancer.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.